Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

But the LillyDirect Zepbound offer is for vials that patients inject themselves with, using an old-fashioned syringe. “It’s a cultural phenomena,” Ricks says of the drug. “It’s used by ...

The LillyDirect self-pay Zepbound single-dose vials require Headrick to use a syringe to draw the medicine and then inject it. He said LillyDirect provided easy-to-follow instructions on using the ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Ignore the noise in GLP-1 stocks. Find the best value instead.

The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

Demand for Wegovy and Zepbound is booming, but supply issues and limited insurance coverage have curtailed access to the pricey medications.